United States · Industrial & Consumer Products · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Evoke Pharma Inc? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -240.09% | 12.24% | 17.99% | 11.51% | 10.24% | 9.8% |
|---|---|---|---|---|---|---|
| ROA | -43.54% | 5.19% | 8.66% | 6.24% | 6.07% | 6.26% |
| Gross Margin | 100% | 88.5% | 88.5% | 88.38% | 88.42% | 88.4% |
| Net Margin | -52.22% | 7.23% | 11.47% | 8.69% | 8.49% | 8.81% |
| Total Assets | $17,519.01K | $17,841.70K | $18,471.57K | $18,839.19K | $19,229.59K | $19,762.82K |
| Net Income | -$5,352.19K | $917.61K | $1,573.15K | $1,163.46K | $1,154.47K | $1,220.88K |